Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) (ARTISTRY-1)

4 november 2026 bijgewerkt door: Gilead Sciences

Een operationeel naadloze fase 2/3 gerandomiseerde, open-label, multicenter, actief gecontroleerde studie ter evaluatie van de veiligheid en werkzaamheid van bictegravir/lenacapavir versus een stabiel baselineregime bij virologisch onderdrukte mensen met hiv-1 die stabiele complexe behandelingsregimes volgen

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

689

Fase

  • Fase 2
  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Buenos Aires, Argentinië, 1202
        • Fundación Huésped
      • Buenos Aires, Argentinië, 1072
        • Hospital General de Agudos J.M Ramon Mejia
      • Buenos Aires, Argentinië, 1425
        • Helios Salud
    • New South Wales
      • Darlinghurst, New South Wales, Australië, 2010
        • St.Vincent's Hospital Sydney
      • Darlinghurst, New South Wales, Australië, 2011
        • Taylor Square Private Clinic
      • Sydney, New South Wales, Australië, 2010
        • Holdsworth House Medical Practice
    • Victoria
      • Melbourne, Victoria, Australië, 3004
        • Alfred Health
      • Decarie Montreal, Canada, H4A 3J1
        • Chronic Viral Illness Service / McGill University Health Centre (MUHC)
      • Montreal, Canada, H2L 0B1
        • Clinique Medicale du Quartier Latin
      • Ottawa, Canada, K1H 8L6
        • The Ottawa Hospital - General Campus
      • Regina, Canada, S4P 0W5
        • ID Clinic
      • Toronto, Canada, M5G 1K2
        • Maple Leaf Research
      • Vancouver, Canada, V6Z 2T1
        • Spectrum Health
      • Santo Domingo, Dominicaanse Republiek
        • Instituto Dominicano de Estudio Virologicos - IDEV
      • Berlin, Duitsland, 10439
        • zibp Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH
      • Bonn, Duitsland, 53127
        • Universitatsklinikum Bonn
      • Frankfurt, Duitsland, 60596
        • Infektio Research GmbH & Co.KG
      • Hamburg, Duitsland, 20146
        • ICH Study Center GmbH & Co. KG
      • München, Duitsland
        • MVZ München am Goetheplatz
      • Nice, Frankrijk, 6202
        • CHU Nice-Hôpital l'Archet
      • Paris, Frankrijk, 75010
        • Hospital Saint Louis
      • Paris, Frankrijk, 75018
        • Groupe Hospitalier Bichat Claude Bernard
      • Paris, Frankrijk, 75651
        • Höpital de la Pitié Salpêtrière
      • Milan, Italië, 20157
        • ASST Fatebenefratelli Sacco
      • Milan, Italië, 20127
        • IRCCS Ospedale San Raffaele
      • Modena, Italië, 40124
        • Azienda Ospedaliero-Universitaria di Modena
      • Roma, Italië, 00149
        • Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS
      • Torino, Italië, 10149
        • ASL Città di Torino
      • Nagoya, Japan
        • National Hospital Organization Nagoya Medical Center
      • Osaka, Japan, 540-0006
        • National Hospital Organization Osaka National Hospital
      • Tokyo, Japan, 162-0052
        • Center Hospital of the National Center for Global Health and Medicine
    • PR
      • San Juan, PR, Puerto Rico, 00909
        • Hope Clinical Research
      • San Juan, PR, Puerto Rico, 00935
        • Proyecto ACTU
      • Barcelona, Spanje, 08036
        • Hospital Clinic Provincial de Barcelona
      • Madrid, Spanje, 28040
        • Hospital Clinico San Carlos
      • Madrid, Spanje, 28046
        • Hospital Universitario La Paz
      • Madrid, Spanje, 28034
        • Hospital Ramon y Cajal, Madrid
      • Seville, Spanje, 4103
        • Hospital Universitario Virgen del Rocio
      • Kaohsiung City, Taiwan, 80756
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Kaohsiung City, Taiwan, 81362
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • New Taipei City, Taiwan, 22060
        • Far Eastern Memorial Hospital
      • Taoyuan City, Taiwan, 33004
        • Taoyuan General Hospital
      • Birmingham, Verenigd Koninkrijk, B9 5SS
        • Department of HIV & Sexual Medicine
      • Brighton, Verenigd Koninkrijk, BN2 3EW
        • Brighton and Sussex University Hospitals NHS Trust
      • London, Verenigd Koninkrijk, E1 1BB.
        • Barts Health NHS Trust
      • London, Verenigd Koninkrijk, SE5 9RS
        • HIV medicine and infectious diseases
      • London, Verenigd Koninkrijk, SW109NH
        • St.Stephen's AIDS Trust, Clinical Trials Unit, 1st Floor, St.Stephen's Centre
    • California
      • Berkeley, California, Verenigde Staten, 48072
        • Be Well Medical Center
      • Beverly Hills, California, Verenigde Staten, 90211
        • Pacific Oaks Medical Group
      • Los Angeles, California, Verenigde Staten, 90036
        • Ruane Clinical Research Group, Inc
      • Oakland, California, Verenigde Staten, 94609
        • Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
      • Palm Springs, California, Verenigde Staten, 92262
        • Bios Clinical Research
      • San Diego, California, Verenigde Staten, 92103
        • University of California San Diego (UCSD)
      • Torrance, California, Verenigde Staten, 90502
        • Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
      • West Hollywood, California, Verenigde Staten, 90046
        • The Men's Health Foundation
    • Colorado
      • Denver, Colorado, Verenigde Staten, 80204
        • Denver Health Medical Center
    • Connecticut
      • New Haven, Connecticut, Verenigde Staten, 06510
        • Yale University; School of Medicine; AIDS Program
    • Florida
      • DeLand, Florida, Verenigde Staten, 32720
        • Midland Florida Clinical Research Center, LLC
      • Fort Lauderdale, Florida, Verenigde Staten, 33316
        • Gary Richmond, MD, PA, Inc.
      • Fort Lauderdale, Florida, Verenigde Staten, 33308
        • Therafirst Medical Centers
      • Ft. Pierce, Florida, Verenigde Staten, 34982
        • Midway Immunology & Research Center, LLC
      • Miami, Florida, Verenigde Staten, 33136
        • Schiff Center for liver Diseases/University of Miami
      • Miami Lakes, Florida, Verenigde Staten, 33016
        • Floridian Clinical Research
      • Orlando, Florida, Verenigde Staten, 32803
        • Orlando Immunology Center
      • Orlando, Florida, Verenigde Staten, 32803
        • Therapeutic Concepts, PA
      • West Palm Beach, Florida, Verenigde Staten, 33407
        • Triple O Research Institute PA
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30309
        • Atlanta ID Group
      • Macon, Georgia, Verenigde Staten, 31201
        • Mercer University School of Medicine
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60613
        • Howard Brown Health Center
    • Missouri
      • Kansas City, Missouri, Verenigde Staten, 64111
        • Kansas City Care Clinic
      • St Louis, Missouri, Verenigde Staten, 63139
        • Southampton Healthcare, Inc.
    • New Jersey
      • Newark, New Jersey, Verenigde Staten, 07102
        • Saint Michael's Medical Center
    • New Mexico
      • Santa Fe, New Mexico, Verenigde Staten, 87505
        • AXCES Research Group
    • New York
      • Flushing, New York, Verenigde Staten, 11355
        • New York Presbyterian Hospital
      • New York, New York, Verenigde Staten, 10001
        • Ricky K. Hsu, MD, PC
    • North Carolina
      • Chapel Hill, North Carolina, Verenigde Staten, 27514
        • University of North Carolina - Chapel Hill
      • Greenville, North Carolina, Verenigde Staten, 27858
        • East Carolina University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19107
        • Philadelphia FIGHT
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29425
        • Medical University of South Carolina (MUSC) Research NEXUS
    • Texas
      • Austin, Texas, Verenigde Staten, 78705
        • Central Texas Clinical Research
      • Bellaire, Texas, Verenigde Staten, 77401
        • St. Hope Foundation
      • Dallas, Texas, Verenigde Staten, 75246
        • North Texas Infectious Diseases Consultants
      • Dallas, Texas, Verenigde Staten, 75208
        • AIDS Arms, Inc., DBA Prism Health North Texas
      • Fort Worth, Texas, Verenigde Staten, 76104
        • Texas Centers for Infectious Disease Associates
      • Houston, Texas, Verenigde Staten, 77098
        • Gordon E. Crofoot MD PA
      • Longview, Texas, Verenigde Staten, 75605
        • Diagnostic Clinic of Longview - Center for Clinical Research
    • Washington
      • Seattle, Washington, Verenigde Staten, 98104
        • Peter Shalit, MD
      • Daegu, Zuid -Korea, 41944
        • Kyungpook National University Hospital
      • Daejeon, Zuid -Korea, 35015
        • Chungnam National University Hospital
      • Seoul, Zuid -Korea, 06591
        • The Catholic University of Korea Seoul St. Mary's Hospital
      • Seoul, Zuid -Korea, 03722
        • Yonsei University Severance Hospital
      • Cape Town, Zuid-Afrika, 7925
        • Desmond Tutu Health Foundation Clinical Trials Unit
      • Ga-Rankuwa, Zuid-Afrika, 208
        • Sefako Makgatho Health Sciences University
      • Johannesburg, Zuid-Afrika, 2193
        • Ezintsha

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Key Inclusion Criteria:

  • If plasma HIV-1 RNA measurements in the 6 months prior to screening are available, all levels must be < 50 copies/mL.

  • At least one documented plasma HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL

  • Plasma HIV-1 RNA levels < 50 copies/mL at screening.

  • Currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, or intolerance, or contraindication to existing single-tablet regimens (STR), and on this regimen for at least 6 months prior to the screening visit. The criteria to define a complex regimen in this study are as follows:

    • A regimen containing a boosted protease inhibitor or a nonnucleos(t)ide reverse transcriptase inhibitor (NRTI) plus at least 1 other third agent (ie, an agent from a class other than NRTIs) (eg, bictegravir/emtricitabine/tenofovir alafenamide (coformulated; Biktarvy®)(BVY) + darunavir/cobicistat, BVY + etravirine), or
    • A regimen of ≥ 2 pills/day, or a regimen requiring dosing more than once daily, or
    • A regimen containing parenteral agent(s) (excluding a complete long-acting injectable regimen, such as intramuscular cabotegravir plus rilpivirine) as well as oral agents.
  • No documented or suspected resistance to bictegravir (BIC).

  • Estimated glomerular filtration rate ≥ 15 mL/min according to the Cockcroft-Gault formula for creatinine clearance (CLcr) who are not on renal replacement therapy.

Key Exclusion Criteria:

  • Prior use of, or exposure to, lenacapavir (LEN)
  • Active tuberculosis infection
  • Chronic hepatitis B virus (HBV) infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg

Participants will switch from their Stable Baseline Regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day pharmacokinetic (PK) oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1.

Participants who discontinue early or complete the Randomized Phase (RP) will have an option to continue in Extension Period (EP)

Tablets administered orally without regard to food

Andere namen:
  • GS-6207

Tablets administered orally without regard to food

Andere namen:
  • GS-9883
Experimenteel: Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg

Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1.

Participants who discontinue early or complete the RP will have an option to continue in EP.

Tablets administered orally without regard to food

Andere namen:
  • GS-6207

Tablets administered orally without regard to food

Andere namen:
  • GS-9883
Actieve vergelijker: Phase 2: Treatment Group 3: SBR

Participants will continue with their SBR for up to 24 weeks.

Participants who discontinue early or complete the RP will have an option to continue in EP.

SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).

  • Nucleos(t)ide Reverse Transcriptase Inhibitors:

    • Abacavir
    • Emtricitabine
    • Lamivudine
    • Tenofovir alafenamide
    • Tenofovir disoproxil fumarate
    • Zidovudine
  • Non-Nucleosite Reverse Transcriptase Inhibitors:

    • Delavirdine
    • Efavirenz
    • Nevirapine
    • Rilpivirine
    • Doravirine
  • Integrase Inhibitors:

    • Bictegravir
    • Cabotegravir
    • Dolutegravir
    • Elvitegravir
    • Raltegravir
  • Protease Inhibitors:

    • Atazanavir
    • Darunavir
    • Fosamprenavir
    • Indinavir
    • Lopinavir
    • Nelfinavir
    • Saquinavir
    • Tipranavir
  • Chemokine Co-receptor 5 (CCR5) Antagonist:

    • Maraviroc
  • Fusion Inhibitors:

    • Enfuvirtide
  • gp120 Attachment Inhibitor:

    • Fostemsavir
  • Anti-CD4 Monoclonal Antibodies:

    • Ibalizumab-uiyk
Experimenteel: Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC

Participants will switch from their SBR to a regimen of BIC/LEN 75mg/50mg FDC, administered orally once daily for up to 48 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1.

Participants who discontinue early or complete the RP will have an option to continue in EP.

Tablets administered orally without regard to food

Andere namen:
  • Bixlenvo™
Actieve vergelijker: Phase 3: Treatment Group 2: SBR

Participants will continue with their SBR for up to 48 weeks.

Participants who will discontinue early or complete the RP had an option to continue in EP.

SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).

  • Nucleos(t)ide Reverse Transcriptase Inhibitors:

    • Abacavir
    • Emtricitabine
    • Lamivudine
    • Tenofovir alafenamide
    • Tenofovir disoproxil fumarate
    • Zidovudine
  • Non-Nucleosite Reverse Transcriptase Inhibitors:

    • Delavirdine
    • Efavirenz
    • Nevirapine
    • Rilpivirine
    • Doravirine
  • Integrase Inhibitors:

    • Bictegravir
    • Cabotegravir
    • Dolutegravir
    • Elvitegravir
    • Raltegravir
  • Protease Inhibitors:

    • Atazanavir
    • Darunavir
    • Fosamprenavir
    • Indinavir
    • Lopinavir
    • Nelfinavir
    • Saquinavir
    • Tipranavir
  • Chemokine Co-receptor 5 (CCR5) Antagonist:

    • Maraviroc
  • Fusion Inhibitors:

    • Enfuvirtide
  • gp120 Attachment Inhibitor:

    • Fostemsavir
  • Anti-CD4 Monoclonal Antibodies:

    • Ibalizumab-uiyk
Experimenteel: Phase 2/Phase 3:BIC/LEN 75/50 mg FDC

At the end of randomized treatment, participants in Phase 2 and Phase 3 treatment groups who discontinue early or complete the RP will be given an option to enter in EP and will receive BIC/LEN 75/50 mg FDC until the drug is available in market or Gilead elects to withdraw the study. Participants in the SBR groups (Phase 2 Treatment Group 3 and Phase 3 Treatment Group 2 will also receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2 of EP).

Tablets administered orally without regard to food

Andere namen:
  • GS-6207

Tablets administered orally without regard to food

Andere namen:
  • Bixlenvo™

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
Tijdsspanne: Week 24

Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Week 24
Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Tijdsspanne: Week 48

Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.

Week 48

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
Tijdsspanne: Week 24

Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Week 24
Phase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
Tijdsspanne: Baseline, Week 24
Baseline, Week 24
Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24
Tijdsspanne: First dose date up to Week 24

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

First dose date up to Week 24
Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State
Tijdsspanne: At Week 16 or 24

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or 24
Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State
Tijdsspanne: At Week 16 or Week 24

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: AUCtau of BIC at Steady State
Tijdsspanne: At Week 16 or 24

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or 24
Phase 2: PK Parameter: AUCtau for LEN at Steady State
Tijdsspanne: At Week 16 or Week 24

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of BIC at Steady State
Tijdsspanne: At Week 16 or Week 24

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of LEN at Steady State
Tijdsspanne: At Week 16 or Week 24

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Tijdsspanne: Week 48

Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively).

Week 48
Phase 3: Change From Baseline in CD4 Cell Count at Week 48
Tijdsspanne: Baseline, Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

Baseline, Week 48
Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48
Tijdsspanne: First dose date up to Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.

First dose date up to Week 48
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Tijdsspanne: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Tijdsspanne: Week 144
Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Tijdsspanne: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Tijdsspanne: Week 144
Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96
Tijdsspanne: Baseline, Week 96
Baseline, Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144
Tijdsspanne: Baseline, Week 144
Baseline, Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 96
Tijdsspanne: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 144
Tijdsspanne: Week 144
Week 144

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

16 augustus 2022

Primaire voltooiing (Werkelijk)

29 september 2025

Studie voltooiing (Geschat)

1 december 2029

Studieregistratiedata

Eerst ingediend

5 augustus 2022

Eerst ingediend dat voldeed aan de QC-criteria

12 augustus 2022

Eerst geplaatst (Werkelijk)

16 augustus 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 november 2026

Laatste update ingediend die voldeed aan QC-criteria

4 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • GS-US-621-6289
  • 2022-500929-33 (Andere identificatie: European Medicines Agency)
  • DOH-27-052023-8574 (Andere identificatie: South African Clinical Trial Registry)
  • jRCT2051230168 (Andere identificatie: Japan registry)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren